DFDA

3HP Regimen (Isoniazid + Rifapentine weekly for 3 months for Latent TB Infection)

Treatment for Drug Susceptible Tuberculosis

Typical Dosage: Isoniazid 900mg weekly, Rifapentine 900mg weekly

Effectiveness
78%
Safety Score
60%
Clinical Trials
15
Participants
10K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Isoniazid 900mg weekly, Rifapentine 900mg weekly
Time to Effect
Prevention initiated within weeks, protective effect over years
Treatment Duration
3 months (weekly)
Evidence Quality
HIGH
Number Needed to Treat (NNT)
12(Treat 12 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
35(Treat 35 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,300
Monitoring:$150
Side Effect Mgmt:$75
Total Annual:$1,525
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$15,000/QALY
QALYs Gained
0.12
Comparison vs Isoniazid (INH) Monotherapy (9 months)
Cost Difference
+$1,200/year
More expensive
QALY Difference
+0.02 QALYs
Better outcomes
Dominance
No dominance
3HP Regimen (Isoniazid + Rifapentine weekly for 3 months for Latent TB Infection) Outcomes

for Drug Susceptible Tuberculosis

Efficacy Outcomes
Overall Effectiveness
+78%
Common Side Effects
Flu-like syndrome
+10%
Rash
+10%
Hepatotoxicity
+5%
GI upset
+8%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov